Hannam & Partners, a leading independent investment bank, issued an independent research report on Psyence Group.

The report identifies the company as a first mover into the palliative care market supported by natural psilocybin production.

It notes that while Psyence has already generated revenue through its functional mushroom joint venture (Psyence Function) and production facility vertical (Psyence Production), it attributes the lion’s share of Psyence’s value to its drug discovery programme and expects a 450 per cent uplift in share price.

Psyence Group Inc. (PSYG) opened trading at C$0.10

More From The Market Online

A compelling Nevada gold story as the Walker Lane reasserts its importance

With gold prices reaching record levels in January 2026, Nevada’s mining districts are once again commanding...

Major West African gold project begins new drill phase after recent Resource Estimate Update

Pelangio Exploration Inc. (TSXV: PX) (OTC Pink: PGXPF) has entered a pivotal new phase in the advancement of its Manfo Project in Ghana.
Organigram

Organigram reports revenue boost in Q1

Organigram (TSX:OGI) reported its Q1 2026 revenue and profit surged, with net revenue up 49 per cent to $63.5M.

Playboy: A solid investment proposition built on licensing, de‑leveraging, and priceless IP

The “household name” gets thrown around a lot, but in this case, it is actually true....